Goldline Pharmaceutical IPO

Small Cap Pharmaceuticals SME

IPO Details

Bidding Dates

12 May '26 - 14 May '26

Minimum Investment

₹2,58,000 / 2 Lots (6,000 Shares)

Price Range

₹41 – ₹43

Maximum Investment

₹2,58,000 / 2 Lots (6,000 Shares)

Retail Discount

To be announced

Issue Size

₹11.61 Cr

Investor category and sub category

Retail Individual Investors (RII) | Non-institutional Investors (NII) | Qualified Institutional Buyers (QIB)

Goldline Pharmaceutical IPO Important Dates

Important dates with respect to IPO allotment and listing

IPO Opening Date

May 12, 26

IPO Closing Date

May 14, 26

Basis of Allotment

May 15, 26

Initiation of Refunds

May 18, 26

IPO Listing Date

May 19, 26

About Goldline Pharmaceutical IPO

Goldline Pharmaceutical IPO is a book-built issue worth ₹11.61 crore. The IPO consists entirely of a fresh issue of 27 lakh equity shares. The IPO opens for subscription on May 12, 2026, and closes on May 14, 2026. The allotment is expected to be finalised on May 15, 2026, with tentative listing on BSE SME scheduled for May 19, 2026.

The IPO is priced in a band of ₹41 - ₹43 per share. Retail investors must apply for a minimum of 2 lots comprising 6,000 shares, requiring an investment of ₹2,58,000 at the upper price band. HNI investors must apply for a minimum of 3 lots (9,000 shares), amounting to ₹3,87,000.

Cumulative Capital Private Limited is the book-running lead manager to the issue, and Bigshare Services Private Limited is the registrar.

For detailed information on company financials, business operations, and associated risks, investors are advised to refer to the Goldline Pharmaceutical IPO RHP.